Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2
Ragonnet-Cronin, M.; Nutalai, R.; Huo, J.; Dijokaite-Guraliuc, A.; Das, R.; Tuekprakhon, A.; Supasa, P.; Liu, C.; Selvaraj, M.; Groves, N.; Hartman, H.; Ellaby, N.; Sutton, J. M.; Bahar, M. W.; Zhou, D.; Fry, E.; Ren, J.; Brown, C.; Klenerman, P.; Dunachie, S. J.; Mongkolsapaya, J.; Hopkins, S.; Chand, M.; Stuart, D. I.; Screaton, G. R.; Rokadiya, S.
Show abstract
Some COVID-19 patients are unable to clear their infection or are at risk of severe disease, requiring treatment with neutralising monoclonal antibodies (nmAb) and/or antivirals. The rapid roll-out of novel therapeutics means there is limited understanding of the likely genetic barrier to drug resistance. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to the detection of emerging drug resistance. Here we report the accrual of mutations in Delta and Omicron cases treated with casirivimab+imdevimab and sotrovimab respectively. Mutations occur within the epitopes of the respective nmAbs. For casirivimab+imdevimab these are present on contiguous raw reads, simultaneously affecting both components. Using surface plasmon resonance and pseudoviral neutralisation assays we demonstrate these mutations reduce or completely abrogate antibody affinity and neutralising activity, suggesting they are driven by immune evasion. In addition, we show that some mutations also reduce the neutralising activity of vaccine-induced serum.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Nanobody-mediated Complement Activation to Kill HIV-infected Cells 93%
- SARS-CoV-2 Worldwide Replication Drives Rapid Rise and Selection of Mutations across the Viral Genome: A Time-Course Study Potential Challenge for Vaccines and Therapies 92%
- Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5 91%
Similar papers in this journal
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
- Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants 94%
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials 93%
Similar papers in this journal
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 95%
- Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination 94%
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 94%
Similar papers in this journal
- Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus 96%
- The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2 93%
- Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.